Effect of platelet inhibition with Cangrelor during PCI on ischemic events

New England Journal of Medicine

Volumn 368, Issue 14, 2013, Pages 1303-1313

  Bhatt, Deepak L ^a   Stone, Gregg W ^b   Mahaffey, Kenneth W ^c   Gibson, C Michael ^d   Steg, P Gabriel ^e   Hamm, Christian W ^f   Price, Matthew J ^g   Leonardi, Sergio ^h   Gallup, Dianne ^c   Bramucci, Ezio ^h   Radke, Peter W ⁱ   Widimský, Petr ^j   Tousek, Frantisek ^k   Tauth, Jeffrey ^l   Spriggs, Douglas ^m   McLaurin, Brent T ⁿ   Angiolillo, Dominick J ^o   Généreux, Philippe ^b   Liu, Tiepu ^p   Prats, Jayne ^p   Todd, Meredith ^p   Skerjanec, Simona ^p   White, Harvey D ^q   Harrington, Robert A ^r   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e INSERM   (France)

^f Kerckhoff Heart and Thorax Center   (Germany)

^g SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j CHARLES UNIVERSITY   (Czech Republic)

^k eské Bud jovice Hospital a s   (Czech Republic)

^l National Park Medical Center   (United States)

^m Clearwater Cardiovascular Consultants   (United States)

ⁿ ANMED HEALTH   (United States)

^o UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^p MEDICINES COMPANY   (United States)

^q Green Lane Cardiovascular Service ^*  (New Zealand)

^r STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; CLOPIDOGREL; PLACEBO;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; TREATMENT OUTCOME;

EID: 84875779761     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1300815     Document Type: Article

References (32)

1. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908-17. (Pubitemid 41029145)
2. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991-1001. [Erratum, N Engl J Med 2012;367:1768.]
3. Bhatt DL. To cath or not to cath: that is no longer the question. JAMA 2005;293: 2935-7. (Pubitemid 41029151)
4. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48:1319-25. (Pubitemid 44436821)
5. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non- ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292:2096-104. (Pubitemid 39435100)
6. Desai NR, Bhatt DL. The state of periprocedural antiplatelet therapy after recent trials. JACC Cardiovasc Interv 2010;3: 571-83.
7. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011;8:547-59.
8. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. (Pubitemid 350106708)
9. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
10. Bhatt DL. Intensifying platelet inhibition - navigating between Scylla and Charybdis. N Engl J Med 2007;357:2078-81. (Pubitemid 350106717)
11. Součková L, Opatrilová R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol 2013;69:309-17.
12. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122:776-81.
13. Frelinger AL III, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013 January 9 [Epub ahead of print].
14. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804.
15. Agrawal K, Bhatt DL. Antiplatelet therapy: does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol 2013 January 15 (Epub ahead of print).
16. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73.
17. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284:1549-58.
18. Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012;34: 44-55.
19. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361:2330-41.
20. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29.
21. Kastrati A, Ndrepepa G. Cangrelor - a champion lost in translation? N Engl J Med 2009;361:2382-4.
22. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163:182-90.
23. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012;163:768-76.
24. Brener SJ, Cristea E, Kirtane AJ, et al. Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv 2013;6:36-43.
25. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009;119: 597-605.
26. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265-74.
27. The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42. [Erratum, N Engl J Med 2010;363:1585.]
28. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233-43.
29. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097- 105. [Erratum, JAMA 2011;305:2174.]
30. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral anti-platelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. [Erratum, JAMA 2003;289:987.] (Pubitemid 35340537)
31. Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012;308:2507-16.
32. Widimsky P, Motovská Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008;29:1495- 503.